Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific

Taki, Junichi; Nakajima, Kénichi; Hwang, Eui-Hyo; Matsunari, Ichiro; Komai, Koichiro; Yoshita, Mitsuhiro; Sakajiri, Kenichi; Tonami, Norihisa

doi:10.1007/s002590050544

Cited by 163 publications

(128 citation statements)

References 26 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…Although a previous report showed that there was no significant difference in the early and delayed H/M ratio among PD patients with a different severity according to the H & Y scale (20), there was no significant decrease in PD-1 patients in this study, probably due to the small number of pa-tients in PD-1. In agreement with another previous studies (21,22), the present results also support the usefulness of 123 I-MIBG myocardial scintigraphy for distinguishing PD-2, 3, 4 and 5 groups from the other 4 groups ( Table 2).…”

Section: Discussionsupporting

confidence: 93%

PSP as Distinguished from CBD, MSA-P and PD by Clinical and Imaging Differences at an Early Stage

et al. 2011

View full text Add to dashboard Cite

Objective Because it is often difficult to precisely diagnose and distinguish progressive supranuclear palsy (PSP) from corticobasal degeneration (CBD), multiple system atrophy-parkinsonism (MSA-P) and Parkinson's disease (PD) at the onset of the disease, we compared the patients and clarified the features of these diseases. Methods We compared 77 PSP, 26 CBD, 26 MSA-P and 166 PD patients from clinical and imaging points of view including cerebral blood flow (CBF) in the frontal eye field. Results The clinical characteristics of PSP were supranuclear gaze disturbance, optokinetic nystagmus (OKN) impairment and falls at the first visit. On head MRI, midbrain tegmentum atrophy was much more frequently detected in PSP than in all of the other groups. Heart-to-mediastinum average count ratio (H/M) in iodine-123 meta-iodobenzyl guanidine ( 123 I-MIBG) myocardial scintigraphy was not decreased in PSP, CBD, MSA-P and PD-Yahr 1 (-1), but patients of PD-2, 3, 4 and 5 showed a significant decrease compared with the PSP group. The CBF in the left frontal eye field of PD-3 group and that in right frontal eye field of PD-3 and PD-4 groups were lower than that of PSP group, although other groups showed a tendency without a significant decrease compared with PSP group. Conclusion PSP is distinguishable from CBD, MSA-P and PD even at the early stage with extra-ocular movement (EOM) disturbance, falls, atrophy of the midbrain tegmentum, and H/M in 123 I-MIBG myocardial scintigraphy, and the reduction of CBF in area 8 could serve as a supplemental diagnostic method for distinguishing PSP from PD-3 or PD-4.

show abstract

Section: Discussionsupporting

confidence: 93%

PSP as Distinguished from CBD, MSA-P and PD by Clinical and Imaging Differences at an Early Stage

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Sympathetic denervation in Parkinson's disease involves loss of post-ganglionic noradrenergic but not cholinergic nerves (Sharabi et al, 2003). Loss of sympathetic innervation is most pronounced in the heart and occurs in both familial and sporadic forms of the disease (Taki et al, 2000;Goldstein et al, 2000Goldstein et al, , 2001.…”

Section: Eisenhofer Et Almentioning

confidence: 99%

Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine

2004

View full text Add to dashboard Cite

“…In Parkinson's disease, loss of cardiac sympathetic innervation is an early finding (Druschky et al, 2000;Ohmura, 2000;Reinhardt et al, 2000;Takatsu et al, 2000), without evidence for a premonitory phase involving a preganglionic lesion; sympathetic denervation is relatively selective for the heart, with normal plasma levels of catecholamines (Goldstein et al, 2000;Takatsu et al, 2000;Taki et al, 2000); and cardiac sympathetic denervation progresses over time, with loss of terminals in the left ventricular free wall or apex occurring faster than loss in the basal anteroseptal myocardium . Finally, although after heart transplantation some cardiac sympathetic reinnervation can occur (Kaye et al, 1993), no report to date has noted evidence for recovery of cardiac sympathetic innervation in humans with Parkinson's disease.…”

Section: Discussionmentioning

confidence: 99%

“…18 F]fluorodopamine-derived radioactivity remain unchanged in most other body organs (Goldstein et al, 2000;Reinhardt et al, 2000;Taki et al, 2000), and levels of norepinephrine in antecubital venous plasma are normal (Senard et al, 1993;Goldstein et al, 2002).…”

mentioning

confidence: 99%

Sympathetic Innervation in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Primate Model of Parkinson's Disease

Goldstein

Li²,

Holmes³

et al. 2003

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Cardiac sympathetic denervation occurs commonly in Parkinson's disease. This study explored whether analogous denervation occurs in primates with Parkinsonism from systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). 6-[18 F]Fluorodopamine positron emission tomographic scanning and plasma levels of catecholamines and their deaminated metabolites were used to assess sympathetic and adrenomedullary function in rhesus monkeys, in the untreated state (n ϭ 3), 2 weeks after a series of four MPTP injections, before establishment of Parkinsonism (acute phase, n ϭ 1); a month later, after four more MPTP doses, associated with severe Parkinsonism (subacute phase, n ϭ 1); or more than 2 years from the last dose (remote phase, n ϭ 3), with persistent severe Parkinsonism. A positive control received i.v. 6-hydroxydopamine 1 week before 6-[18 F]fluorodopamine scanning. Acute MPTP treatment increased cardiac 6-[18 F]fluorodopamine-derived radioactivity, whereas 6-hydroxydopamine markedly decreased cardiac radioactivity, despite similarly low plasma levels of catecholamines and metabolites after either treatment. Subacutely, plasma catecholamines remained decreased, but now with myocardial 6-[18 F]fluorodopamine-derived radioactivity also decreased. Remotely, MPTP-treated monkeys had lower plasma catecholamines and higher myocardial 6-[18 F]fluorodopamine-derived radioactivity than did untreated animals. The results indicate that in nonhuman primates, systemic MPTP administration produces multiphasic effects on peripheral catecholamine systems, with nearly complete recovery by 2 years. MPTP-and 6-hydroxydopamine-induced changes differ markedly, probably from ganglionic or preganglionic neurotoxicity with the former and more severe cardiac sympathetic neurotoxicity with the latter. Because of multiphasic sympathetic and adrenomedullary effects, without cardioselective sympathetic denervation at any time, the primate MPTP model does not mimic the changes in peripheral catecholamine systems that characterize the human disease.Parkinson's disease features cardiac sympathetic denervation, as evidenced by decreased myocardial concentrations of radioactivity after administration of the sympathoneural imaging agents 123 I-metaiodobenzylguanidine (Satoh et al

show abstract

Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific

Cited by 163 publications

References 26 publications

PSP as Distinguished from CBD, MSA-P and PD by Clinical and Imaging Differences at an Early Stage

PSP as Distinguished from CBD, MSA-P and PD by Clinical and Imaging Differences at an Early Stage

Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine

Sympathetic Innervation in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Primate Model of Parkinson's Disease

Contact Info

Product

Resources

About